09/ 787,426

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

NEWS EXPRESS	January 6 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability

09/ 787,426

```
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 16:18:33 ON 30 JAN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:18:43 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 JAN 2003  HIGHEST RN 483275-57-6
DICTIONARY FILE UPDATES:  29 JAN 2003  HIGHEST RN 483275-57-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09787426.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 C,H,S,N,Cy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:19:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   5442 TO ITERATE

 18.4% PROCESSED    1000 ITERATIONS                              5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       104419 TO   113261
PROJECTED ANSWERS:             232 TO      856

L2             5 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:19:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 108279 TO ITERATE

100.0% PROCESSED  108279 ITERATIONS                           396 ANSWERS
SEARCH TIME: 00.00.06

L3           396 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              148.15     148.36

FILE 'CAPLUS' ENTERED AT 16:19:27 ON 30 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 30 Jan 2003  VOL 138 ISS 5
FILE LAST UPDATED: 29 Jan 2003  (20030129/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 31 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 31 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:226646 CAPLUS
DOCUMENT NUMBER: 137:154785
TITLE: Molecular recognition of modified nucleobases. Self-complementarity and base-pairing of betainic guanine model compounds
AUTHOR(S): Schmidt, Andreas; Kobakhidze, Nikoloz; Kindermann, Markus Karl
CORPORATE SOURCE: Institut fuer Organische Chemie, Technische Universitaet Clausthal, Clausthal-Zellerfeld, D-38678, Germany
SOURCE: Journal of the Chemical Society, Perkin Transactions 1 (2002), (7), 982-990
CODEN: JCSPCE; ISSN: 1472-7781
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:154785
GI



I

AB Cross-conjugated models, e.g. I, of the natural modified RNA-nucleobase 7-methylguanosine, which is a conjugated mesomeric betaine, were synthesized and their self-complementarity and base-pairing properties were studied. Nucleophilic substitution of heteroaroms. with 2-amino-6-chloropyrimidin-4-ol in 1,2-dichlorobenzene and subsequent treatment of the resulting pyrimidinylheteroarenium salts with the anion exchange resin Amberlite IRA-93 in its hydroxy form gave the title compds. almost quant. Electrospray ionization mass spectrometry (ESIMS) and 1H NMR titrns. reveal that the title compds. are self-complementary mols. which form homo-intermol. dimers. Semiempirical as well as ab initio calcns. predict analogous geometries of the dimers and lead to considerable stabilization energies in comparison to the monomeric species. In ESI mass spectrometry, the mol. masses of noncovalent 1:1 assocs. between the model compds. and the complementary nucleobase cytosine and the nucleoside cytidine can be detected. An ab initio calcn. leads to a stabilization energy of 71.3 kJ mol-1 on base-pairing of the mesomeric betaine I with cytosine. Addnl., dimeric 1:1 assocs. can be detected between I and the self-complementary d(CpGp) as a DNA model compd.

IT **345951-76-0P 446021-37-0P 446021-38-1P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aminopyrimidinolate nucleobases via heteroarenium chlorides and self-complementarity and base-pairing mol. recognition studies using ESIMS, 1H NMR, and ab initio calcns.)

RN 345951-76-0 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-4-(dimethylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

RN 446021-37-0 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

RN 446021-38-1 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-4-(1-pyrrolidinyl)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

IT **345951-78-2P 446021-39-2P 446021-40-5P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of aminopyrimidinolate nucleobases via heteroarenium chlorides and self-complementarity and base-pairing mol. recognition studies using ESIMS, 1H NMR, and ab initio calcns.)

RN 345951-78-2 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-4-(dimethylamino)-, inner salt (9CI) (CA INDEX NAME)



RN 446021-39-2 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-, inner salt (9CI) (CA INDEX NAME)



RN 446021-40-5 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-4-(1-pyrrolidinyl)-, inner salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:201429 CAPLUS
DOCUMENT NUMBER: 138:4569
TITLE: Solid phase synthesis of structurally diverse tetra substituted pyrimidines for potential use in combinatorial chemistry
AUTHOR(S): Chauhan, P. M. S.; Kumar, Arun
CORPORATE SOURCE: Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226001, India
SOURCE: Combinatorial Chemistry and High Throughput Screening (2002), 5(1), 93-95
CODEN: CCHSFU; ISSN: 1386-2073
PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A new pyrimidine based scaffold has been identified for generation of combinatorial libraries using solid phase technique. The utility of the scaffolds was demonstrated by synthesizing small libraries of 12 substituted pyrimidines I (Ar = 4-ClC6H4, 3-BrC6H4, 2-HO-5-BrC6H3, 4-HOC6H4, etc.).

IT **476436-93-8P 476436-94-9P**
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid phase synthesis of a tetra-substituted pyrimidine library via cyclocondensation reaction of resin bound thiourea with Et cyanoacetate and arylaldehydes)

RN 476436-93-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(butylamino)-1,4-dihydro-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 476436-94-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(butylamino)-1,4-dihydro-4-oxo-6-(2-pyridinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:116972 CAPLUS
DOCUMENT NUMBER: 137:125132
TITLE: Syntheses of novel antimycobacterial combinatorial libraries of structurally diverse substituted pyrimidines by three-component solid-phase reactions
AUTHOR(S): Kumar, Arun; Sinha, Sudhir; Chauhan, Prem M. S.
CORPORATE SOURCE: Medicinal Chemistry Division, Central Drug Research Institute, U.P., Lucknow, 226001, India
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(4), 667-669
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:125132
AB A new pyrimidine based scaffold has been developed by three-component solid-phase syntheses. The utility of scaffolds was demonstrated by synthesizing libraries of 80 substituted pyrimidines. Among 80 compds. screened, six compds. showed in vitro activity against Mycobacterium tuberculosis(MABA) at a concn. of 50 and 25 .mu.g/mL.
IT **443970-98-7P 443970-99-8P 443971-00-4P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
(prepn. of antimycobacterial combinatorial libraries of pyrimidines by three-component solid-phase reactions)
RN 443970-98-7 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-(octylamino)-4-oxo-6-(3-pyridinyl)-(9CI) (CA INDEX NAME)



RN 443970-99-8 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-4-oxo-2-(propylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 443971-00-4 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-2-[[2-(4-morpholinyl)ethyl]amino]-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:713340 CAPLUS
DOCUMENT NUMBER: 135:272981
TITLE: Preparation of 2-(arylalkylamino)pyrimidones and 2-(heteroarylalkylamino)pyrimidones for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta.
INVENTOR(S): Almario Garcia, Antonio; Ando, Ryoichi; Aritomo, Keiichi; Frost, Jonathan Reid; Li, Adrien Tak; Shoda, Aya; Uehara, Fumiaki; Watanabe, Kazutoshi
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001070727	A1	20010927	WO 2001-EP3638	20010322	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1136484	A1	20010926	EP 2000-400804	20000323	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1136099	A1	20010926	EP 2000-400805	20000323	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1136491	A1	20010926	EP 2000-400806	20000323	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001270884	A2	20011002	JP 2000-81938	20000323	

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:272981

GI



I

AB The title compds. [I; R2 = H, perhalogenated alkyl, (un)substituted alkyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or a halogen; and when n = 1-10, the R1 = unsubstituted naphth-1-yl, unsubstituted naphth-2-yl, aryl, etc.; when n = 4-10 then R1 can represent in addn. an unsubstituted Ph; and when n = 1-3 and R1 = unsubstituted Ph then R2 = perhalogenated alkyl or substituted alkyl] and their pharmaceutically acceptable salts which are used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3.beta., were prepd. and formulated. The compds. I were synthesized by reacting Et 3-(4-pyridyl)-3-oxopropionate (prepn. given) with R1(CH2)nNR2C(:NH)NH2 or by reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (prepn. given) with R1(CH2)nNHR2. The compds. I such as I [R1 = 3,4-(MeO)2C6H3; R2 = H; R3 = 4-pyridyl] showed IC50's of 0.01-10 .mu.M against GSK3.beta..

IT **361484-66-4P 361484-67-5P 361484-68-6P**
361542-10-1P 361542-11-2P 361542-12-3P
361542-13-4P 361542-14-5P 361542-15-6P
361542-16-7P 361542-17-8P 361542-18-9P
361542-19-0P 361542-20-3P 361542-21-4P
361542-22-5P 361542-23-6P 361542-24-7P
361542-25-8P 361542-26-9P 361542-27-0P
361542-28-1P 361542-29-2P 361542-30-5P
361542-31-6P 361542-32-7P 361542-33-8P

361542-34-9P 361542-35-0P 361542-36-1P
361542-37-2P 361542-38-3P 361542-39-4P
361542-40-7P 361542-41-8P 361542-42-9P
361542-43-0P 361542-44-1P 361542-45-2P
361542-46-3P 361542-47-4P 361542-48-5P
361542-49-6P 361542-50-9P 361542-51-0P
361542-52-1P 361542-54-3P 361542-55-4P
361542-56-5P 361542-57-6P 361542-58-7P
361542-59-8P 361542-60-1P 361542-61-2P
361542-62-3P 361542-63-4P 361542-64-5P
361542-65-6P 361542-66-7P 361542-67-8P
361542-68-9P 361542-69-0P 361542-70-3P
361542-71-4P 361542-72-5P 361542-73-6P
361542-75-8P 361542-76-9P 361542-77-0P
361542-78-1P 361542-79-2P 361542-80-5P
361542-82-7P 361542-84-9P 361542-85-0P
361542-86-1P 361542-87-2P 361542-89-4P
362048-04-2P 362048-06-4P 362048-07-5P
362048-08-6P 362048-09-7P 362048-10-0P
362048-12-2P 362048-13-3P 362048-14-4P
362601-30-7P 362601-35-2P 362601-36-3P
362601-37-4P 362601-38-5P 362601-39-6P
362601-41-0P 362601-42-1P 362601-43-2P
362601-44-3P 362601-45-4P 362601-47-6P
362601-49-8P 362601-50-1P 362601-51-2P
362601-52-3P 362601-54-5P 362601-55-6P
362601-56-7P 362601-58-9P 362601-59-0P
362601-60-3P 362601-61-4P 362601-62-5P
362601-64-7P 362601-65-8P 362601-67-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(arylalkylamino)pyrimidones and 2-(heteroarylalkylamino)pyrimidones for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta.)

RN 361484-66-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-furanylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-67-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-68-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-10-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-11-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-12-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-13-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-14-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-15-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-16-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-17-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-18-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-19-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-20-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-21-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-22-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-nitrophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-23-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-24-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-25-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-26-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-27-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-28-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 361542-29-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-30-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-31-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-32-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-naphthalenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-33-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-34-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-35-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-37-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-fluorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-38-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-39-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-40-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]
amino]- (9CI) (CA INDEX NAME)



RN 361542-41-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-42-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-nitrophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-43-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-aminophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-44-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-45-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-46-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-47-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-48-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-49-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-50-9 CAPLUS
CN Acetamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-
pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-51-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-52-1 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-
pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-54-3 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-55-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-56-5 CAPLUS
CN Benzamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-57-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-58-7 CAPLUS
CN Methanesulfonamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-59-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-60-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-61-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-

pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-62-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-63-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-64-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-65-6 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[3-(4-methylphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-66-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-67-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-68-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-69-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-70-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-71-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-72-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(4-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-73-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-75-8 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]methylamino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-76-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-77-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3,4-dimethoxyphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-78-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-[1,1'-biphenyl]-4-ylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-79-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-80-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-82-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-84-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-85-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-86-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-87-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-89-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-04-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-06-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-07-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-08-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-09-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-10-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-12-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-13-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-14-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-30-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-pyridinylmethoxy)phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-35-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362601-36-3 CAPLUS
CN Acetamide, N-[4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 362601-37-4 CAPLUS
CN Methanesulfonamide, N-[4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]- (9CI) (CA INDEX NAME)



RN 362601-38-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl](phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-39-6 CAPLUS
CN Carbamic acid, [4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl](2-phenylethyl)amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 362601-41-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)(2-phenylethyl)amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-42-1 CAPLUS
CN Carbamic acid, [4-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl][2-(2-methoxyphenyl)ethyl]amino]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 362601-43-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362601-44-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-aminobutyl)(3-phenylpropyl)amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 362601-45-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-naphthalenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 362601-47-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[2-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362601-49-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[2-[3-(4-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-50-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-phenylpropyl)(trifluoromethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-51-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 362048-04-2
CMF C19 H17 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362601-52-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-54-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-55-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-56-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[(4-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 362601-58-9 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-59-0 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(4-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362601-60-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl[2-(2-pyridinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-61-4 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[3-(3-pyridinyl)propyl]amino]-
(9CI) (CA INDEX NAME)



RN 362601-62-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(phenylmethyl)[2-(2-pyridinyl)ethyl]amino]-6-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-64-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-phenylethyl)(3-pyridinylmethyl)amino]-6-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-65-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-phenylethyl)(2-pyridinylmethyl)amino]-6-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



RN 362601-67-0 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(3-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:709747 CAPLUS
DOCUMENT NUMBER: 135:257262
TITLE: Preparation of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3.beta. inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136491	A1	20010926	EP 2000-400806	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:257262

09/ 787,426

GI



I

AB The title compds. [I; R1 = H, alkyl; R2 = (un)substituted furyl, thienyl, pyrrolyl or imidazolyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy or halogen; n = 1-5] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta. such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal trauma, and peripheral neuropathies, were prepd. and formulated. Thus, reacting 2-(methylthio)-6-(pyridin-4-yl)pyrimidin-4(1H)-one (prepn. given) with 3-furylmethylamine afforded I [R1 = H; R2 = 3-furyl; R3 = 4-pyridyl; n = 1]. The exemplified compds. I showed IC50's of 0.3-10 .mu.M against GSK3.beta..

IT **361484-66-4P 361484-67-5P 361484-68-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-[(heteroaryl)alkylamino]pyrimidones as GSK3.beta. inhibitors)

RN 361484-66-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(3-furanylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-67-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361484-68-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:709744 CAPLUS
DOCUMENT NUMBER: 135:257260
TITLE: Preparation of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino]pyrimidones as GSK3.beta. inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136486	A1	20010926	EP 2000-400808	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070725	A1	20010927	WO 2001-EP3636	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: EP 2000-400808 A 20000323
OTHER SOURCE(S): MARPAT 135:257260
GI



I

AB The title compds. [I; R1 = H, alkyl; R2 = H, alkyl, halo, etc.; R3 = 2-, 3- or 4-pyridyl group optionally substituted by alkyl, alkoxy or a halogen atom; n = 0-1; when n = 0 then m = 2 or 3, and when n = 1 then m = 1 or 2] which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta. such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents and brain and spinal trauma and peripheral neuropathies, were prepd. and formulated. E.g., a 3-step synthesis of I [R1, R2 = H; R3 = 4-pyridyl; n, m = 1] which showed IC50 of 0.1 .mu.M against GSK3.beta., was given.

IT **361458-95-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-[(indanylamino]pyrimidones and 2-[tetrahydronaphthalenylamino]pyrimidones as GSK3.beta. inhibitors)

RN 361458-95-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:709742 CAPLUS
DOCUMENT NUMBER: 135:257258
TITLE: Preparation of 2-(arylalkylamino)pyrimidones as GSK3.beta. inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Watanabe, Kazutoshi
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136484	A1	20010926	EP 2000-400804	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:
EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323

OTHER SOURCE(S): MARPAT 135:257258
GI



I



II

AB The title compds. [I; R1 = unsubstituted naphth-1-yl, unsubstituted naphth-2-yl, substituted aryl; when n = 4-5 then R1 can represent unsubstituted Ph; R2 = H, alkyl; R3 = 2-, 3- or 4-pyridyl optionally substituted by alkyl, alkoxy group or a halogen atom] which are used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta., were prepd. and formulated. The compds. I were prepd. by reacting the propionate R3COCH2COOR with the amidine R1(CH2)nNR2C(:NH)NH2 or by reacting the pyrimidinone II with amine R1(CH2)nNHR2. All exemplified compds. I such as I [R1 = 3,4-(MeO)2C6H3; R2 = H; R3 = 4-pyridyl; n = 1] showed IC50 of 0.01-10 .mu.M against GSK3.beta..

IT **361542-10-1P 361542-11-2P 361542-12-3P**
361542-13-4P 361542-14-5P 361542-15-6P
361542-16-7P 361542-17-8P 361542-18-9P
361542-19-0P 361542-20-3P 361542-21-4P
361542-22-5P 361542-23-6P 361542-24-7P
361542-25-8P 361542-26-9P 361542-27-0P
361542-28-1P 361542-29-2P 361542-30-5P
361542-31-6P 361542-32-7P 361542-33-8P
361542-34-9P 361542-35-0P 361542-36-1P
361542-37-2P 361542-38-3P 361542-39-4P
361542-40-7P 361542-41-8P 361542-42-9P
361542-43-0P 361542-44-1P 361542-45-2P

361542-46-3P 361542-47-4P 361542-48-5P
361542-49-6P 361542-50-9P 361542-51-0P
361542-52-1P 361542-53-2P 361542-54-3P
361542-55-4P 361542-56-5P 361542-57-6P
361542-58-7P 361542-59-8P 361542-60-1P
361542-61-2P 361542-62-3P 361542-63-4P
361542-64-5P 361542-65-6P 361542-66-7P
361542-67-8P 361542-68-9P 361542-69-0P
361542-70-3P 361542-71-4P 361542-72-5P
361542-73-6P 361542-74-7P 361542-75-8P
361542-76-9P 361542-77-0P 361542-78-1P
361542-79-2P 361542-80-5P 361542-81-6P
361542-82-7P 361542-83-8P 361542-84-9P
361542-85-0P 361542-86-1P 361542-87-2P
361542-88-3P 361542-89-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-(arylalkylamino)pyrimidones as GSK3.beta. inhibitors)

RN 361542-10-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3,4-dimethoxyphenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-11-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-12-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-13-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-

(9CI) (CA INDEX NAME)



RN 361542-14-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-15-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-16-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-17-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-18-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-19-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-20-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-21-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-22-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-nitrophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-23-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-24-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-25-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-26-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-27-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-28-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-
pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 361542-29-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-30-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-31-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-32-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-naphthalenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-33-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-34-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-35-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methylphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-37-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-fluorophenyl)methyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-38-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-39-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-40-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[4-(trifluoromethyl)phenyl]methyl]
amino]- (9CI) (CA INDEX NAME)



RN 361542-41-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-
pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-42-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-nitrophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-43-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-44-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-45-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-methylphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-46-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-47-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-methoxyphenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-48-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-chlorophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-49-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(4-aminophenyl)methyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-50-9 CAPLUS
CN Acetamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-51-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-52-1 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(2-pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-53-2 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(3-pyridinyl)propoxy]phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-54-3 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-55-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(3-aminophenyl)methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-56-5 CAPLUS
CN Benzamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-57-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-58-7 CAPLUS
CN Methanesulfonamide, N-[[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 361542-59-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[(2-pyrimidinylamino)methyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-60-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-61-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-62-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-63-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-64-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methylphenyl)propyl]amino]-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



RN 361542-65-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methylphenyl)propyl]amino]-6-(4-pyridinyl)-

(9CI) (CA INDEX NAME)



RN 361542-66-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-67-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-68-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-methoxyphenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-69-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(2-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-70-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-71-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(4-chlorophenyl)propyl]amino]-6-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 361542-72-5 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(4-
pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-73-6 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-(3-
pyridinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-74-7 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[2-(2-pyridinyl)ethoxy]phenyl]methyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-75-8 CAPLUS
CN Carbamic acid, [[3-[[[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]methylamino]methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361542-76-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361542-77-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[3-(3,4-dimethoxyphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-78-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-[1,1'-biphenyl]-4-ylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-79-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-80-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(aminomethyl)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-81-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-82-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-83-8 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[3-(3-pyridinyl)propoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-84-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[4-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-85-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-[(butylamino)methyl]phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-86-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(2-aminoethoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-87-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(4-aminobutoxy)phenyl]methyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 361542-88-3 CAPLUS
CN 4(1H)-Pyrimidinone, 6-(4-pyridinyl)-2-[[[3-[2-(2-pyridinyl)ethoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 361542-89-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:709740 CAPLUS
DOCUMENT NUMBER: 135:257256
TITLE: Preparation of 2-amino-3-alkyl-pyrimidones as GSK3.beta. inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak; Ando, Ryoichi; Watanabe, Kazutoshi
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136482	A1	20010926	EP 2000-400800	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070729	A1	20010927	WO 2001-EP3640	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1276738	A1	20030122	EP 2001-959921	20010322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: EP 2000-400800 A 20000323
WO 2001-EP3640 W 20010322
OTHER SOURCE(S): MARPAT 135:257256
GI



I

AB The title compds. [I; R1 = H, alkyl; R2 = (un)substituted alkyl, alkenyl, aryl, etc.; or R1 and R2 form together (un)substituted alkylene; or R1 and R2 form together (CH2)2X(CH2)2, (CH2)2X(CH2)3 (wherein X = O, S (un)substituted NH); R3 = 2-, 3- or 4-pyridyl group optionally substituted by alkyl alkoxy or halogen atom; R4 = alkyl optionally substituted by aryl], useful for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta. such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal trauma, and peripheral neuropathies, were prepd. and formulated. The compds. I synthesized by reacting 3-methyl-2-(methylthio)-6-pyridin-4-ylpyrimidin-4(3H)-one (prepn. given) with the corresponding amine or by N-alkylation of the substituted 2-amino-3-methylpyrimidinone with alkyl iodide. The compds. I showed IC50's of 0.1-10 .mu.M against GSK3.beta..

IT **362013-60-3P 362013-61-4P 362013-62-5P**
362013-63-6P 362013-64-7P 362013-65-8P
362013-66-9P 362013-67-0P 362013-68-1P
362013-69-2P 362013-70-5P 362013-71-6P
362013-72-7P 362013-73-8P 362013-74-9P
362013-75-0P 362013-76-1P 362013-77-2P
362013-78-3P 362013-79-4P 362013-80-7P
362013-81-8P 362013-82-9P 362013-83-0P
362013-84-1P 362013-85-2P 362013-86-3P
362013-87-4P 362013-88-5P 362013-89-6P
362013-90-9P 362013-91-0P 362013-92-1P
362013-93-2P 362013-94-3P 362013-95-4P
362013-96-5P 362013-97-6P 362013-98-7P
362014-02-6P 362014-03-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-amino-3-alkyl-pyrimidones as GSK3.beta. inhibitors)

RN 362013-60-3 CAPLUS

CN 4(3H)-Pyrimidinone, 3-methyl-2-[(2-phenylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-61-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[[2-(4-methoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-62-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-methoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-63-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-methoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-64-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-65-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-66-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-67-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-bromophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-68-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-69-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2,4-dichlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-70-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-aminophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-71-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-72-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-73-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-chlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-74-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-75-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(4-methylphenyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-76-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 362013-77-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(3-chlorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-78-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[[2-(2-thienyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 362013-79-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(4-phenylbutyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-80-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-[4-(phenylmethoxy)phenyl]ethyl]amino]-6-

(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-81-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-82-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-83-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2-methoxyphenyl)methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-84-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2,5-dimethoxyphenyl)ethyl]methylamino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-85-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362013-86-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 362013-87-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-(phenylmethyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-88-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-3-methyl-6-(4-

pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-89-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-3-methyl-6-(4-pyridinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362013-88-5
CMF C20 H19 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362013-90-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-91-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-92-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-93-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-94-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[methyl[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-95-4 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(cyclopentylamino)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-96-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(ethylamino)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362013-97-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(ethylamino)-3-methyl-6-(4-pyridinyl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362013-96-5
CMF C12 H14 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362013-98-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362014-02-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(3-aminopropoxy)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362014-03-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[[3-(aminomethyl)phenyl]methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:709694 CAPLUS
DOCUMENT NUMBER: 135:262238
TITLE: Preparation of 2-(indolylalkylamino)pyrimidone derivatives as gsk3beta inhibitors
INVENTOR(S): Almario-Garcia, Antonio; Frost, Jonathan Reid; Li, Adrien-Tak
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.; Mitsubishi-Tokyo Pharmaceuticals, Inc.
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1136099	A1	20010926	EP 2000-400805	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
WO 2001070727	A1	20010927	WO 2001-EP3638	20010322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: EP 2000-400804 A 20000323
EP 2000-400805 A 20000323
EP 2000-400806 A 20000323
JP 2000-81938 A 20000323
OTHER SOURCE(S): MARPAT 135:262238
GI



I

AB A pyrimidone deriv. represented by formula I or a salt thereof: wherein: R1 represents a hydrogen atom or a C1-6 alkyl group; R2 represents a hydrogen atom or a C1-6 alkyl group; R3 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4 alkyl group, a C1-4 alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group, methylenedioxy group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group, C2-12 dialkylamino group, a C1-6 alkylcarbonylamino group, C6-10 arylcarbonylamino group, a Ph group or a benzyloxy group; and n represents 1 to 5. And a medicament comprising the said deriv. or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3.beta. (as glycogen synthase kinase 3.beta.)such as Alzheimer's disease, Parkinson's disease, frontoparietal dementia, corticobasal degeneration, Pick's disease, cerebrovascular accidents, brain and spinal cord trauma and peripheral neuropathies. A soln. of 2-(methylthio)-6-pyridinyl-4-ylpyrimidin-4(1H)-one and different indolylalkylamines in amyl alc. were heated at 150.degree. for 72 h to obtain 2-[indolylalkylamino]-6-pyridin-4-ylpyrimidin-4(1H)-one derivs. Inhibitory activity of the above derivs. against gsk3.beta. was tested. A tablet contained a 2-(indolylalkylamino)pyrimidone deriv. 30, cryst. cellulose 60, corn starch 100, lactose 200, and magnesium stearate 4 mg.

IT **362048-05-3P 362048-06-4P 362048-07-5P**
362048-08-6P 362048-09-7P 362048-10-0P
362048-11-1P 362048-12-2P 362048-13-3P
362048-14-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indolylalkylaminopyrimidone derivs. as glycogen synthase kinase inhibitors)

RN 362048-05-3 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)-,

ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 362048-04-2
CMF C19 H17 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 362048-06-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-07-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(5-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-08-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-09-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-methoxy-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-10-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(6-fluoro-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-11-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(7-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-12-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1H-indol-3-yl)ethyl]methylamino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-13-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 362048-14-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(1-methyl-1H-indol-3-yl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:635876 CAPLUS
DOCUMENT NUMBER: 135:211049
TITLE: Preparation of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders
INVENTOR(S): Borroni, Edilio Maurizio; Huber-Trottmann, Gerda; Kilpatrick, Gavin John; Norcross, Roger David
PATENT ASSIGNEE(S): F. Hoffmann La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001062233 A2 20010830 WO 2001-EP1679 20010215
WO 2001062233 A3 20020103
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1261327 A2 20021204 EP 2001-927670 20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2001027196 A1 20011004 US 2001-788956 20010220
NO 2002004006 A 20020822 NO 2002-4006 20020822
PRIORITY APPLN. INFO.: EP 2000-103432 A 20000225
WO 2001-EP1679 W 20010215
OTHER SOURCE(S): MARPAT 135:211049
GI



I



II

AB The title compds. (I) [wherein A = a bond, S, N(R), (CH2)2, CH:CH, C.tplbond.C, or O; X and Y = independently N:, :N, :CH, C(CN):, :C(CN), C(CSNH2):, or :C(CSNH2), wherein at least 1 of X or Y is N; R1 = H, (cyclo)alkyl, alkenyl, alkynyl, halo, CN, (alkyl)carboxylates, (alkyl)carbamates, alkoxy(alkyl), phenoxy(alkyl), phenylamino(alkyl), (un)substituted phenyl(alkyl) or amino(alkyl), morpholinyl(alkyl), piperidinyl(alkyl), pyridinyl(alkyl), piperazinyl(alkyl), etc.; R2 = H, halo, CN, NO2, acyl, carboxylate, (un)substituted alkyl, alkenyl, alkynyl, or Ph; R3 = alkyl or thienyl, (dihydro)furanyl, benzodioxolyl, isoxazolyl, pyridinyl, dihydropyranyl, pyrazinyl, aryl(alkyl)oxy, pyrazolyl, (un)substituted Ph, etc.; R4 and R5 = independently H, benzoyl, or (un)substituted phenacyl; or A and R2 taken together the with the C atoms to which they are attached may form a substituted thienyl group] were prepd. as adenosine receptor modulators. For example, treating 3,4,5-trimethoxybenzoylacetonitrile with to NaH in DMSO, followed by addn. of CS2 and MeI, gave the bis(methylthio) intermediate. Cycloaddn. with guanidine nitrate in the presence of TEA in DMF afforded the pyrimidinenitrile (II), which exhibited high selectivity toward the A1 and A3 adenosine receptors compared to the A2 receptor with pKi values of 5.88, 5.71 and 7.24, resp. I are useful for the treatment of Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, and sedation, and they may be active as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants, and cardioprotective agents (no data). The most preferred indications for I are those which include disorders of the

central nervous system, such as certain depressive disorders, neuroprotection, and Parkinson's disease.

IT **357288-62-1P 357288-63-2P 357288-67-6P 357288-71-2P 357288-72-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders and other diseases)

RN 357288-62-1 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-pyridinyl)-6-(2-pyridinylmethoxy)- (9CI) (CA INDEX NAME)



RN 357288-63-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-pyridinyl)-6-[2-(2-pyridinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 357288-67-6 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-amino-4-[(3,5-dimethyl-2-pyridinyl)methoxy]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 357288-71-2 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-amino-4-[(3-methyl-2-pyridinyl)methoxy]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 357288-72-3 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-amino-4-[(5-methyl-2-pyridinyl)methoxy]-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:267520 CAPLUS
DOCUMENT NUMBER: 135:61296
TITLE: Synthesis of self-complementary betainic guanine model compounds
AUTHOR(S): Schmidt, Andreas; Kindermann, Markus Karl
CORPORATE SOURCE: Technische Universitat Clausthal, Institut fur Organische Chemie, Clausthal-Zellerfeld, D-38678, Germany
SOURCE: Chemistry Letters (2001), (4), 348-349
CODEN: CMLTAG; ISSN: 0366-7022
PUBLISHER: Chemical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:61296

AB Reaction of 4-(dimethylamino)pyridine and 1-methylimidazole with 2-amino-4-chloro-6-hydroxypyrimidine resulted in the formation of pyrimidine-heteroarenium salts. These could be deprotonated using an anion exchange resin to yield pyridinium-pyrimidinolates as model compds. for biol. highly important betainic guanines present in RNA. As proved by ESIMS, these cross-conjugated mesomeric betaines are self-complementary and form homo-intermol. dimers.

IT **345951-76-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(self-complementary betainic guanine model compds.)
RN 345951-76-0 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-4-(dimethylamino)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

IT **345951-78-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(self-complementary betainic guanine model compds.)
RN 345951-78-2 CAPLUS
CN Pyridinium, 1-(2-amino-1,6-dihydro-6-oxo-4-pyrimidinyl)-4-(dimethylamino)-, inner salt (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:531662 CAPLUS
DOCUMENT NUMBER: 133:120343
TITLE: Preparation of arylpyrimidinones and analogs as drugs
INVENTOR(S): Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: U.S., 92 pp., Cont.-in-part of U.S. Ser. No. 976,053, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6096753	A	20000801	US 1997-985346	19971204
ZA 9710727	A	19980612	ZA 1997-10727	19971128
CN 1246857	A	20000308	CN 1997-181558	19971204
ZA 9710911	A	19980605	ZA 1997-10911	19971205
US 6420385	B1	20020716	US 2000-504509	20000215
US 6410729	B1	20020625	US 2000-598740	20000621

PRIORITY APPLN. INFO.:
US 1996-32128P P 19961205
US 1997-50950P P 19970613
US 1997-976053 B2 19971121
US 1997-976054 B2 19971121
US 1997-984774 B1 19971204
US 1997-985346 A3 19971204

OTHER SOURCE(S): MARPAT 133:120343
GI



I

AB Title compds. [e.g., I; Z = N or CR2; R1,R2 = R or Z1R; R = H, halo, alkoxy(carbonyl), amino(carbonyl or sulfonyl), etc.; R3 = Z1R; R4,R5 = (un)substituted (hetero)aryl; X = O, S, (un)substituted imino; Z1 = alkylene, heterocyclylene, (hetero)arylene, etc.] were prepd. as agents for redn. of, e.g., TNF-.alpha. levels. Thus, 4-FC6H4CH2CO2Et was acylated by Et isonicotinate and the product cyclocondensed with (H2N)2CS to give, after N-methylation, I (R3 = Me, R4 = C6H4F-4, R5 = 4-pyridyl, X = O)(II; R1 = SH) which was aminated by 2-FC6H4CH(NH2)CH2CH2NH2 to give II [R1 = NHCH2CH2CH(NH2)C6H4F-2]. Data for biol. activity of I were given.

IT **208652-78-2P 208652-79-3P 208652-80-6P**
208652-81-7P 208652-82-8P 208652-83-9P
208652-84-0P 208652-85-1P 208652-86-2P
208652-87-3P 208652-88-4P 208652-89-5P
208652-90-8P 208652-91-9P 208652-92-0P
208652-93-1P 208652-94-2P 208652-95-3P
208652-96-4P 208652-97-5P 208652-99-7P
208653-00-3P 208653-02-5P 208653-04-7P
208653-05-8P 208653-06-9P 208653-08-1P
208653-10-5P 208653-12-7P 208653-14-9P
208653-16-1P 208653-18-3P 208653-20-7P
208653-22-9P 208653-23-0P 208653-24-1P
208653-25-2P 208653-26-3P 208653-27-4P
208653-28-5P 208653-30-9P 208653-31-0P
208653-32-1P 208653-33-2P 208653-34-3P
208653-35-4P 208653-36-5P 208653-37-6P
208653-38-7P 208653-39-8P 208653-40-1P
208653-41-2P 208653-42-3P 208653-43-4P
208653-44-5P 208653-45-6P 208653-46-7P
208653-48-9P 208653-49-0P 208653-50-3P
208653-51-4P 208653-57-0P 208653-58-1P
208653-59-2P 208653-60-5P 208653-61-6P
208653-62-7P 208653-84-3P 208653-86-5P
208653-87-6P 208653-88-7P 208653-89-8P
208653-90-1P 208653-91-2P 208653-92-3P
208653-93-4P 208653-94-5P 208653-95-6P
208653-96-7P 208653-97-8P 208653-98-9P
208653-99-0P 208654-03-9P 208654-04-0P
208654-05-1P 208654-06-2P 208654-07-3P
208654-08-4P 208654-09-5P 208654-10-8P
208654-11-9P 208654-12-0P 208654-13-1P
208654-14-2P 208654-15-3P 208654-16-4P
208654-17-5P 208654-18-6P 208654-19-7P
208654-20-0P 208654-21-1P 208654-22-2P
208654-23-3P 208654-24-4P 208654-25-5P
208654-26-6P 208654-27-7P 208654-28-8P
208654-29-9P 208654-30-2P 208654-31-3P
208654-32-4P 208654-33-5P 208654-34-6P
208654-35-7P 208654-36-8P 208654-37-9P
208654-38-0P 208654-39-1P 208654-40-4P
208654-41-5P 208654-42-6P 208654-43-7P
208654-44-8P 208654-45-9P 208654-46-0P
208654-47-1P 208654-48-2P 208654-49-3P

208654-50-6P 208654-51-7P 208654-52-8P
208654-53-9P 208654-54-0P 208654-55-1P
208654-56-2P 208654-58-4P 208654-59-5P
208654-60-8P 208654-62-0P 208654-63-1P
208654-65-3P 208654-67-5P 208654-68-6P
208654-69-7P 208654-70-0P 208654-72-2P
208654-73-3P 208654-74-4P 208654-75-5P
208654-76-6P 208654-77-7P 208654-78-8P
208654-79-9P 208654-80-2P 208654-81-3P
208654-83-5P 208654-86-8P 208654-87-9P
208654-89-1P 208654-90-4P 208654-92-6P
208654-94-8P 208654-96-0P 208654-97-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylpyrimidinones and analogs as drugs)

RN 208652-78-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(butylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-79-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-(pentylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-80-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3,3-dimethylbutyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-81-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-82-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[(4-fluorophenyl)methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-83-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[(3-fluorophenyl)methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-84-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[1-(3-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-85-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-86-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[2-(4-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-87-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2-fluorophenyl)-2-[[2-(3-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-88-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2-fluorophenyl)-2-[[2-(2-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-89-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2-fluorophenyl)-2-[(2-hydroxy-2-phenylethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-90-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-91-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-92-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(1R)-1-methyl-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208652-93-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3,3-diphenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-94-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[2-(phenylamino)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-95-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-96-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[2-(1-piperazinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-97-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-2-[[3-(1-pyrrolidinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 208652-99-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-00-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(ethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-02-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-amino-2-methyl-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-04-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(aminomethyl)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-05-8 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-06-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-08-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-10-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-12-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-(methylamino)-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-14-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[2-(phenylthio)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-16-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(2-hydroxyethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-18-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-20-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2,2-dimethyl-3-(phenylthio)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-22-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-23-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-methylphenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-24-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-25-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-26-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R,3R)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-27-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S,3S)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-28-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-hydroxy-3-phenylpropyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-30-9 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(2-amino-4-pyridinyl)-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-31-0 CAPLUS
CN Acetamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-32-1 CAPLUS
CN Acetamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 208653-33-2 CAPLUS
CN Acetamide, 2-(acetyloxy)-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-34-3 CAPLUS
CN Acetamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 208653-35-4 CAPLUS
CN Methanesulfonamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-36-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-[2-[(phenylmethyl)amino]-

4-pyridinyl]-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-37-6 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-6-[2-[[(2-methoxyphenyl)methyl]amino]-4-pyridinyl]-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-38-7 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[2-(ethylamino)-4-pyridinyl]-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-39-8 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[2-[bis(3-methylbutyl)amino]-4-pyridinyl]-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-40-1 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[2-(diethylamino)-4-pyridinyl]-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-41-2 CAPLUS
CN Urea, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 208653-42-3 CAPLUS
CN Urea, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 208653-43-4 CAPLUS
CN Acetamide, 2-amino-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-44-5 CAPLUS
CN Butanamide, 4-amino-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-45-6 CAPLUS
CN Propanamide, 3-amino-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-46-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-6-(2-amino-4-pyridinyl)-5-(4-fluorophenyl)-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-48-9 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(2-amino-4-pyridinyl)-2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-49-0 CAPLUS
CN Acetamide, N-[4-[2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-50-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-6-(2-amino-4-pyridinyl)-5-(4-fluorophenyl)-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-51-4 CAPLUS
CN Benzenepropanamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(phenylmethyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-57-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-58-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-59-2 CAPLUS

CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-60-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-61-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-62-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-(4-fluorophenyl)-6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 208653-84-3 CAPLUS
CN Acetamide, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208653-86-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-87-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(cyclohexylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-88-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(butylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-89-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-90-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-91-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-92-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-ethyl-5-(4-fluorophenyl)-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-93-4 CAPLUS
CN Acetamide, 2-amino-N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-94-5 CAPLUS
CN Acetamide, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208653-95-6 CAPLUS
CN Urea, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208653-96-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-3-phenyl-2-(1-pyrrolidinyl)propyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-97-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3S)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-98-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3R)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-99-0 CAPLUS
CN Acetamide, N-[(1S)-3-[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-03-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-3-(2-chlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-04-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(3,4-dichlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-05-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(4-chlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-06-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-07-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(4-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-08-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(1-naphthalenyl)propyl]amino]-5-(4-

fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-09-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-2-phenylethyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-10-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-4-(methylthio)butyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-11-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-cyclohexylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-12-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2,3-dihydro-1H-indol-2-yl)methyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-13-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-amino-3-benzo[b]thien-3-ylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-14-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-15-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-16-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(4-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-17-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-18-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-[3-(1-methylethyl)phenyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-19-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3-chloro-4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-20-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-[3,5-bis(trifluoromethyl)phenyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-21-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3,4-dichlorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-22-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(1-naphthalenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-23-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3-

fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-24-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3,4-dimethylphenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-25-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3,5-dichlorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-26-6 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-(4-methylphenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-27-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-28-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-methoxyphenyl)-3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-29-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-30-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-31-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-5-(1-naphthalenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-32-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-33-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-34-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-5-(3,4-dimethylphenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-35-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-[4-(methylthio)phenyl]-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-36-8 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-[4-(methylsulfonyl)phenyl]-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-37-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208654-38-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208654-39-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208654-40-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-2,2-dimethyl-3-phenylpropyl)amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208654-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-2,2-dimethyl-3-phenylpropyl)amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208654-42-6 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 208654-43-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(2-hydroxy-2-phenylethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-44-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-45-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-46-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(ethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-47-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-amino-2-methyl-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-48-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(aminomethyl)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-49-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-50-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-51-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-52-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(butylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-53-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-54-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-55-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-56-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-ethyl-5-(4-fluorophenyl)-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-58-4 CAPLUS
CN Acetamide, 2-amino-N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-59-5 CAPLUS
CN Acetamide, 2-amino-N-[(1S)-1-[[[1,6-dihydro-1-methyl-5-(3-methylphenyl)-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-60-8 CAPLUS

09/ 787,426

CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-3-phenyl-2-(1-pyrrolidinyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-62-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-methylphenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-63-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-65-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-67-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-68-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-69-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-70-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-methylphenyl)propyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-72-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-fluorophenyl)propyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-73-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-74-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-fluorophenyl)propyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-75-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-chlorophenyl)propyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-76-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-5-(3,4-dimethylphenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-77-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R,3R)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-78-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S,3S)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-79-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3S)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-80-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3R)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-81-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-83-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-86-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(2-chlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-87-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-89-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 208654-90-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3-chlorophenyl)-3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-92-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-94-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(3-chlorophenyl)-2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-96-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-97-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-(methylamino)-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/ 787,426

IT **208655-27-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylpyrimidinones and analogs as drugs)
RN 208655-27-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2-bromophenyl)methyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:227649 CAPLUS
DOCUMENT NUMBER: 132:265206
TITLE: Preparation of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease
INVENTOR(S): Watanabe, Kazutoshi; Ando, Ryoichi; Saito, Ken-ichi; Kawamoto, Rie; Shoda, Aya
PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018758	A1	20000406	WO 1999-JP5224	19990924
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345065	AA	20000406	CA 1999-2345065	19990924
AU 9957599	A1	20000417	AU 1999-57599	19990924
EP 1115721	A1	20010718	EP 1999-944815	19990924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002525366	T2	20020813	JP 2000-572218	19990924

PRIORITY APPLN. INFO.: JP 1998-271277 A 19980925
JP 1998-305266 A 19981027
WO 1999-JP5224 W 19990924
OTHER SOURCE(S): MARPAT 132:265206

09/ 787,426

GI



I

AB The title compds. [I; R1 = C1-18 alkyl, C3-18 alkenyl, C3-18 alkenyl, etc.; R2 = H, OH, C1-18 alkyl, etc.; R3 = (un)substituted pyridyl], useful for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as Alzheimer disease, were prepd. and formulated. Thus, reacting Et 3-(4-pyridyl)-3-oxopropionate with 3-amidinopyridine.HCl in the presence of K2CO3 in EtOH afforded I [R1 = 3-pyridyl; R2 = H; R3 = 4-pyridyl] which showed IC50 of 2.3 .mu.M against P-GS1 phosphorylation by bovine cerebral TPK1.

IT **54950-12-8P 54950-14-0P 54950-15-1P**
263244-09-3P 263244-10-6P 263244-16-2P
263244-25-3P 263244-26-4P 263244-27-5P
263244-30-0P 263244-31-1P 263244-32-2P
263244-34-4P 263244-35-5P 263244-36-6P
263244-37-7P 263244-38-8P 263244-39-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrimidones for treating diseases caused by tau protein kinase 1 hyperactivity such as Alzheimer disease)

RN 54950-12-8 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-14-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-15-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-09-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-chloro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-10-6 CAPLUS
CN Benzamide, N-[1,4-dihydro-4-oxo-6-(4-pyridinyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 263244-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(diethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-25-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-26-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-27-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3,3-diphenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-30-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[methyl(2-methylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-31-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dipropylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-32-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-hydroxypropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-34-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(cyclohexylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-35-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-ethylphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-36-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(4-butoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-37-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-bromophenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-38-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(phenylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 263244-39-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[(3-methoxyphenyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:287423 CAPLUS
DOCUMENT NUMBER: 131:18977
TITLE: Synthesis of pyrimidines and azolopyrimidines as biodynamic agents
AUTHOR(S): Upadhyay, D. N.; Ram, Vishnu J.
CORPORATE SOURCE: Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226 001, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1999), 38B(2), 173-177
CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER: National Institute of Science Communication, CSIR
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB 5-Cyano-6-(4-pyridyl)-2-thiouracil (I) has been synthesized and used as a precursor for the synthesis of mono- and bicyclic pyrimidine derivs., e.g., II and III, to evaluate their antifungal and antileishmanial activities.

IT **226092-80-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(pyrimidines and azolopyrimidines as biodynamic agents)

RN 226092-80-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-hydrazino-1,4-dihydro-4-oxo-6-(4-pyridinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:402295 CAPLUS
DOCUMENT NUMBER: 129:76492
TITLE: Method for treating multiple sclerosis
INVENTOR(S): Buxser, Stephen E.; Fitzpatrick, Francis A.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA; Buxser, Stephen E.; Fitzpatrick, Francis A.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825596	A2	19980618	WO 1997-US21402	19971203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9856871	A1	19980703	AU 1998-56871	19971203
EP 948331	A2	19991013	EP 1997-953042	19971203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001505911	T2	20010508	JP 1998-526700	19971203

PRIORITY APPLN. INFO.: US 1996-32648P P 19961212
WO 1997-US21402 W 19971203

OTHER SOURCE(S): MARPAT 129:76492

AB A method for treating multiple sclerosis by systemic administration of a 6-aryl pyrimidine compd. or a pharmaceutically acceptable salt thereof in assocn. with a pharmaceutical carrier to a human having symptoms of multiple sclerosis.

IT **98305-53-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of exptl. autoimmune encephalomyelitis as model of multiple sclerosis with 6-arylpyrimidines)

RN 98305-53-4 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:394334 CAPLUS
DOCUMENT NUMBER: 129:67791
TITLE: Preparation of 2-substituted 5-(4-fluorophenyl)-4-(4-pyridyl)pyrimidines and related compounds as drugs
INVENTOR(S): Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
PATENT ASSIGNEE(S): Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.
SOURCE: PCT Int. Appl., 232 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824782	A2	19980611	WO 1997-US22390	19971204

WO 9824782	A3	19980827		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9710727	A	19980612	ZA 1997-10727	19971128
AU 9860120	A1	19980629	AU 1998-60120	19971204
EP 948497	A2	19991013	EP 1997-954778	19971204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9713850	A	20000229	BR 1997-13850	19971204
CN 1246858	A	20000308	CN 1997-181563	19971204
JP 2002514195	T2	20020514	JP 1998-525850	19971204
ZA 9710911	A	19980605	ZA 1997-10911	19971205
MX 9905168	A	20000228	MX 1999-5168	19990603
US 6410729	B1	20020625	US 2000-598740	20000621

PRIORITY APPLN. INFO.:

US 1996-32128P	P	19961205
US 1997-50950P	P	19970613
US 1997-976054	A	19971121
US 1997-984774	B1	19971204
WO 1997-US22390	W	19971204

OTHER SOURCE(S): MARPAT 129:67791

GI



I

AB Novel pyrimidines [I; R1, R2 = ZY, with a proviso; Z = bond, (un)substituted alk(en)yl, alkynyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl; etc; Y = H, halo, NO2, COR20, CNR5NR5R21, OR21, O2CR21, etc.; R5 = H, (un)substituted alk(en)yl, alkynyl, cycloalkyl, (hetero)aryl, etc.; R20 = (un)substituted alk(en)yl, alkynyl, aralkoxy, aralkylthio, aralkylsulfonyl, etc.; R21 = H, any of definitions for R20] and their pharmaceutically acceptable salts, effective for prophylaxis and treatment of diseases mediated by tumor necrosis factor .alpha. (TNF-.alpha.), IL-1.beta., IL-6 and/or IL-8 and other maladies, e.g., pain and diabetes, were prepd., e.g., by enamination of 2-(4-fluorophenyl)-1-(4-pyridinyl)ethanone (II) with (Me2N)2CHOMe and cyclocondensation of the resulting (dimethylamino)propenone with an amidine, guanidine or urea. I analogs, prodrugs , pharmaceutical compns., methods for prophylaxis and treatment of diseases or conditions involving inflammation, pain, diabetes, etc., and processes for making such compds. and their intermediates are also claimed. For example, heating a mixt. of II with (Me2N)2CHOMe at 110.degree. for 1.5 h under Ar gave 3-(dimethylamino)-2-(4-fluorophenyl)-1-(4-pyridyl)-3-propen-1-one which was cyclocondensed with 4-pyridylamidine (prepd. in situ from pyridylamidine-HCl and Na) by refluxing in EtOH to give a title compd. I (R1 = R12 = 4-pyridinyl, R2 = H, R11 = 4-FC6H4). The latter in mice inhibited lipopolysaccharide-induced TNF-.alpha. release with IC50 .ltoreq.20 .mu.M.

IT **208654-44-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-acetylation with acetic anhydride; prepn. of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)
RN 208654-44-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **208653-57-0P 208653-58-1P 208653-59-2P**
208653-60-5P 208653-61-6P 208653-62-7P
208653-84-3P 208654-53-9P 208654-54-0P
208654-55-1P 208654-56-2P 208654-83-5P
208936-36-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-substituted (fluorophenyl)(pyridyl)pyrimidines and related compds. as drugs)
RN 208653-57-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-58-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-59-2 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-60-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-61-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-62-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-(4-fluorophenyl)-6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 208653-84-3 CAPLUS
CN Acetamide, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-53-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-54-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-55-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-56-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-ethyl-5-(4-fluorophenyl)-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-83-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208936-36-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[methyl(2-phenylethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:394333 CAPLUS
DOCUMENT NUMBER: 129:54384
TITLE: Preparation of arylpyrimidinones and analogs as drugs
INVENTOR(S): Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
PATENT ASSIGNEE(S): Amgen Inc., USA; Spohr, Ulrike D.; Malone, Michael J.; Mantlo, Nathan B.; Zablocki, Jeff A.
SOURCE: PCT Int. Appl., 298 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824780	A2	19980611	WO 1997-US22949	19971204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9710727	A	19980612	ZA 1997-10727	19971128
AU 9855254	A1	19980629	AU 1998-55254	19971204
AU 735901	B2	20010719		
EP 948496	A2	19991013	EP 1997-951678	19971204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1246857	A	20000308	CN 1997-181558	19971204
BR 9713863	A	20000314	BR 1997-13863	19971204
JP 2002514196	T2	20020514	JP 1998-525902	19971204
ZA 9710911	A	19980605	ZA 1997-10911	19971205
MX 9905158	A	20000331	MX 1999-5158	19990603
US 6410729	B1	20020625	US 2000-598740	20000621

PRIORITY APPLN. INFO.:	US 1996-32128P	P	19961205
	US 1997-50950P	P	19970613
	US 1997-976053	A	19971121
	US 1997-976054	B2	19971121
	US 1997-984774	B1	19971204
	WO 1997-US22949	W	19971204

OTHER SOURCE(S): MARPAT 129:54384

GI



I

AB Title compds. [e.g., I; Z = N or CR2; R1,R2 = R or Z1R; R = H, halo, alkoxy(carbonyl), amino(carbonyl or sulfonyl), etc.; R3 = Z1R; R4,R5 = (un)substituted (hetero)aryl; X = O, S, (un)substituted imino; Z1 = alkylene, heterocyclylene, (hetero)arylene, etc.] were prepd. as agents for redn. of, e.g., TNF-.alpha. levels. Thus, 4-FC6H4CH2CO2Et was acylated by Et isonicotinate and the product cyclocondensed with (H2N)2CS to give, after N-methylation, I (R3 = Me, R4 = C6H4F-4, R5 = 4-pyridyl, X = O)(II; R1 = SH) which was aminated by 2-FC6H4CH(NH2)CH2CH2NH2 to give II [R1 = NHCH2CH2CH(NH2)C6H4F-2]. Data for biol. activity of I were given.

IT **208652-78-2P 208652-79-3P 208652-80-6P**
208652-81-7P 208652-82-8P 208652-83-9P
208652-84-0P 208652-85-1P 208652-86-2P
208652-87-3P 208652-88-4P 208652-89-5P
208652-90-8P 208652-91-9P 208652-92-0P
208652-93-1P 208652-94-2P 208652-95-3P
208652-96-4P 208652-97-5P 208652-99-7P
208653-00-3P 208653-02-5P 208653-04-7P
208653-05-8P 208653-06-9P 208653-08-1P
208653-10-5P 208653-12-7P 208653-14-9P
208653-16-1P 208653-18-3P 208653-20-7P
208653-22-9P 208653-23-0P 208653-24-1P

208653-25-2P 208653-26-3P 208653-27-4P
208653-28-5P 208653-30-9P 208653-31-0P
208653-32-1P 208653-33-2P 208653-34-3P
208653-35-4P 208653-36-5P 208653-37-6P
208653-38-7P 208653-39-8P 208653-40-1P
208653-41-2P 208653-42-3P 208653-43-4P
208653-44-5P 208653-45-6P 208653-46-7P
208653-48-9P 208653-49-0P 208653-50-3P
208653-51-4P 208653-57-0P 208653-58-1P
208653-59-2P 208653-60-5P 208653-61-6P
208653-62-7P 208653-84-3P 208653-86-5P
208653-87-6P 208653-88-7P 208653-89-8P
208653-90-1P 208653-91-2P 208653-92-3P
208653-93-4P 208653-94-5P 208653-95-6P
208653-96-7P 208653-97-8P 208653-98-9P
208653-99-0P 208654-03-9P 208654-04-0P
208654-05-1P 208654-06-2P 208654-07-3P
208654-08-4P 208654-09-5P 208654-10-8P
208654-11-9P 208654-12-0P 208654-13-1P
208654-14-2P 208654-15-3P 208654-16-4P
208654-17-5P 208654-18-6P 208654-19-7P
208654-20-0P 208654-21-1P 208654-22-2P
208654-23-3P 208654-24-4P 208654-25-5P
208654-26-6P 208654-27-7P 208654-28-8P
208654-29-9P 208654-30-2P 208654-31-3P
208654-32-4P 208654-33-5P 208654-34-6P
208654-35-7P 208654-36-8P 208654-37-9P
208654-38-0P 208654-39-1P 208654-40-4P
208654-41-5P 208654-42-6P 208654-43-7P
208654-44-8P 208654-45-9P 208654-46-0P
208654-47-1P 208654-48-2P 208654-49-3P
208654-50-6P 208654-51-7P 208654-52-8P
208654-53-9P 208654-54-0P 208654-55-1P
208654-56-2P 208654-58-4P 208654-59-5P
208654-60-8P 208654-62-0P 208654-63-1P
208654-65-3P 208654-67-5P 208654-68-6P
208654-69-7P 208654-70-0P 208654-72-2P
208654-73-3P 208654-74-4P 208654-75-5P
208654-76-6P 208654-77-7P 208654-78-8P
208654-79-9P 208654-80-2P 208654-81-3P
208654-83-5P 208654-86-8P 208654-87-9P
208654-89-1P 208654-90-4P 208654-92-6P
208654-94-8P 208654-96-0P 208654-97-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylpyrimidinones and analogs as drugs)

RN 208652-78-2 CAPLUS

CN 4(3H)-Pyrimidinone, 2-(butylamino)-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-79-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-(pentylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-80-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3,3-dimethylbutyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-81-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(phenylmethyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-82-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[(4-fluorophenyl)methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-83-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[(3-fluorophenyl)methyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-84-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[1-(3-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-85-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-86-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[2-(4-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-87-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2-fluorophenyl)-2-[[2-(3-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-88-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2-fluorophenyl)-2-[[2-(2-fluorophenyl)ethyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-89-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(2-fluorophenyl)-2-[(2-hydroxy-2-phenylethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-90-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-91-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-92-0 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(1R)-1-methyl-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208652-93-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3,3-diphenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-94-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[2-(phenylamino)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-95-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-96-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[2-(1-piperazinyl)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208652-97-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-2-[[3-(1-pyrrolidinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 208652-99-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-00-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(ethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-02-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-amino-2-methyl-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-04-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(aminomethyl)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-05-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-06-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[3-(2-methylphenyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-08-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-10-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-12-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-(methylamino)-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-14-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[2-(phenylthio)ethyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-16-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(2-hydroxyethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-18-3 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-20-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2,2-dimethyl-3-(phenylthio)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-22-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-23-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-methylphenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-24-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-25-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-26-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R,3R)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-27-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S,3S)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-28-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-hydroxy-3-phenylpropyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-30-9 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(2-amino-4-pyridinyl)-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-31-0 CAPLUS
CN Acetamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-32-1 CAPLUS
CN Acetamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 208653-33-2 CAPLUS
CN Acetamide, 2-(acetyloxy)-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-34-3 CAPLUS
CN Acetamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 208653-35-4 CAPLUS
CN Methanesulfonamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-36-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-[2-[(phenylmethyl)amino]-

4-pyridinyl]-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-37-6 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-6-[2-[[(2-methoxyphenyl)methyl]amino]-4-pyridinyl]-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-38-7 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[2-(ethylamino)-4-pyridinyl]-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-39-8 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[2-[bis(3-methylbutyl)amino]-4-pyridinyl]-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-40-1 CAPLUS
CN 4(3H)-Pyrimidinone, 6-[2-(diethylamino)-4-pyridinyl]-5-(4-fluorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]- (9CI) (CA INDEX NAME)



RN 208653-41-2 CAPLUS
CN Urea, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-N'-phenyl- (9CI) (CA INDEX NAME)



RN 208653-42-3 CAPLUS
CN Urea, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 208653-43-4 CAPLUS
CN Acetamide, 2-amino-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-44-5 CAPLUS
CN Butanamide, 4-amino-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-45-6 CAPLUS
CN Propanamide, 3-amino-N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(3-phenylpropyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-46-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-6-(2-amino-4-pyridinyl)-5-(4-fluorophenyl)-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-48-9 CAPLUS
CN 4(3H)-Pyrimidinone, 6-(2-amino-4-pyridinyl)-2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-49-0 CAPLUS
CN Acetamide, N-[4-[2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-50-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-6-(2-amino-4-pyridinyl)-5-(4-fluorophenyl)-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-51-4 CAPLUS
CN Benzenepropanamide, N-[4-[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-2-[(phenylmethyl)amino]-4-pyrimidinyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 208653-57-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[2-(2-chlorophenyl)ethyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-58-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-59-2 CAPLUS

CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(1-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-60-5 CAPLUS
CN 4(1H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208653-61-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-62-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-(4-fluorophenyl)-6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 208653-84-3 CAPLUS
CN Acetamide, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208653-86-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-87-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(cyclohexylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-88-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(butylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-89-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-90-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-91-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-92-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-ethyl-5-(4-fluorophenyl)-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208653-93-4 CAPLUS
CN Acetamide, 2-amino-N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-94-5 CAPLUS
CN Acetamide, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208653-95-6 CAPLUS
CN Urea, N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]-N'-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208653-96-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-3-phenyl-2-(1-pyrrolidinyl)propyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-97-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3S)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-98-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3R)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208653-99-0 CAPLUS
CN Acetamide, N-[(1S)-3-[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-03-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-3-(2-chlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-04-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(3,4-dichlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-05-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(4-chlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-06-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-07-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(4-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-08-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(1-naphthalenyl)propyl]amino]-5-(4-

fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-09-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-2-phenylethyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-10-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-4-(methylthio)butyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-11-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-cyclohexylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-12-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2,3-dihydro-1H-indol-2-yl)methyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-13-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-amino-3-benzo[b]thien-3-ylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-14-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-15-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-16-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(4-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-17-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-18-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-[3-(1-methylethyl)phenyl]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-19-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3-chloro-4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-20-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-[3,5-bis(trifluoromethyl)phenyl]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-21-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3,4-dichlorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-22-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(1-naphthalenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-23-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3-

fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-24-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(3,4-dimethylphenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-25-5 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3,5-dichlorophenyl)-3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-26-6 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-(4-methylphenyl)-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-27-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-28-8 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-methoxyphenyl)-3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-29-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(3-phenylpropyl)amino]-6-(4-pyridinyl)-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-30-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-31-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-5-(1-naphthalenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-32-4 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-33-5 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-34-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-5-(3,4-dimethylphenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-35-7 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-[4-(methylthio)phenyl]-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-36-8 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-5-[4-(methylsulfonyl)phenyl]-6-(4-pyridinyl)-2-[[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-37-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208654-38-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208654-39-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 208654-40-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-2,2-dimethyl-3-phenylpropyl)amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208654-41-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-2,2-dimethyl-3-phenylpropyl)amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 208654-42-6 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)-2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 208654-43-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-2-[(2-hydroxy-2-phenylethyl)amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-44-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-45-9 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-46-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(ethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-47-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2-amino-2-methyl-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-48-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-(aminomethyl)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-49-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-50-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[2-amino-3-(2-fluorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-51-7 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-52-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(butylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-53-9 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-54-0 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-55-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-ethyl-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-56-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3-ethyl-5-(4-fluorophenyl)-2-[(2-methyl-3-phenylpropyl)amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-58-4 CAPLUS
CN Acetamide, 2-amino-N-[(1S)-1-[[[5-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-59-5 CAPLUS
CN Acetamide, 2-amino-N-[(1S)-1-[[[1,6-dihydro-1-methyl-5-(3-methylphenyl)-6-oxo-4-(4-pyridinyl)-2-pyrimidinyl]amino]methyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-60-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-3-phenyl-2-(1-pyrrolidinyl)propyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-62-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-methylphenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-63-1 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-65-3 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-67-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-68-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3R)-3-amino-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-69-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-70-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-methylphenyl)propyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-72-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-fluorophenyl)propyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 208654-73-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(3-amino-3-phenylpropyl)amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-74-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-fluorophenyl)propyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-75-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[3-amino-3-(2-chlorophenyl)propyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 208654-76-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(3S)-3-amino-3-phenylpropyl]amino]-5-(3,4-dimethylphenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-77-7 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2R,3R)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-78-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S,3S)-3-amino-2-methyl-3-phenylpropyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-79-9 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3S)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-80-2 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(3R)-3-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-81-3 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-83-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-[[(2S)-2-amino-3-phenylpropyl]amino]-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-86-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-amino-3-(2-chlorophenyl)propyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-87-9 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-89-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 208654-90-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(3-chlorophenyl)-3-methyl-2-[[(2S)-2-[(1-methylethyl)amino]-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-92-6 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-3-methyl-5-(3-methylphenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-94-8 CAPLUS

CN 4(3H)-Pyrimidinone, 5-(3-chlorophenyl)-2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-96-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2S)-2-(dimethylamino)-3-phenylpropyl]amino]-3-methyl-6-(4-pyridinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 208654-97-1 CAPLUS
CN 4(3H)-Pyrimidinone, 5-(4-fluorophenyl)-3-methyl-2-[[(2S)-2-(methylamino)-3-phenylpropyl]amino]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **208655-27-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylpyrimidinones and analogs as drugs)
RN 208655-27-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[[(2-bromophenyl)methyl]amino]-5-(4-fluorophenyl)-3-methyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:59167 CAPLUS
DOCUMENT NUMBER: 116:59167
TITLE: Chemotherapeutic agents. XXI. Synthesis of .pi.-deficient pyrimidines as leishmanicides
AUTHOR(S): Ram, Vishnu J.
CORPORATE SOURCE: Med. Chem. Div., Cent. Drug Res. Inst., Lucknow, India
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1991), 324(11), 837-9
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



II

III



IV

AB 5-Cyano-6-(3-pyridyl)-2-thiouracil (I) was prepd. from 3-pyridinecarboxaldehyde, thiourea, and Et cyanoacetate. Alkylation of I with mono- and dihaloalkanes under different conditions, gave alkylated derivs. e.g. II (R = MeS, PhCH2S) and III. Halogenation of II (R =

PhCH2S) with POCl3 followed by nucleophilic substitution with amines gave the corresponding amines, e.g. IV. Fusion of II (R = MeS) with arom. and heterocyclic amines at 160.degree. gave the substitution products e.g. II (R = 4-methylpiperazino). Some of the compds. were screened for antileishmanial activity but only one of them IV demonstrated very significant activity.

IT **138429-65-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 138429-65-9 CAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[(4-chlorophenyl)amino]-1,4-dihydro-4-oxo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:207184 CAPLUS
DOCUMENT NUMBER: 106:207184
TITLE: Antitumor activity of pyrimidinones, a class of small-molecule biological response modifiers
AUTHOR(S): Li, Li H.; Wallace, Tanya L.; Wierenga, Wendell; Skulnick, Harvey I.; DeKoning, Thomas F.
CORPORATE SOURCE: Cancer Viral Dis. Res., Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Biological Response Modifiers (1987), 6(1), 44-55
CODEN: JBRMDS; ISSN: 0732-6580
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

Cited by applicant

AB The structure-activity relationship of pyrimidinones was evaluated. Of the 20 pyrimidinones tested I (R1= halo, R2 = Ph or substituted Ph, etc.), only those with a monohalogen substitution at the ortho- or meta-position of the Ph moiety of the 2-amino-5-halo-6-phenyl-4(3H)-pyrimidinone and ABPP (I; R1 = Br; R2 = Ph) [56741-95-8] showed significant synergism with cyclophosphamide (CY) [50-18-0] against P388 leukemia. Therefore, ABMFPP (I; R1 = Br, R2 = 2-FC6H4) [74602-59-8], AIMFPP (I; R1 = I, R2 = 2-FC6H4) [74602-60-1], and ABPP were selected for detailed therapeutic evaluation. The pyrimidinones alone had small activity against B16 melanoma with slightly >25% increase in lifespan (ILS); however, when used in combination with CY, ABPP or ABMFPP did not yield an effect greater than treatment with CY alone. Only AIMFPP appeared to produce a more or less

additive effect with CY. Although none of these pyrimidinones alone had any significant activity against M5076 tumor, the combination with CY (100 mg/kg) produced a range of 102 to 123% ILS and 6-9 of 10 mice per group survived >45 days, whereas the treatment with CY alone yielded only a 48% ILS and none survived >45 days. The synergism of the combination therapy was significant. The combination used against L1210 leukemia also appeared to be superior to the treatment with CY alone and produced 25 to 50% long-term survivors (>30 days). The significance of these findings is discussed in terms of its clin. implications and the effects of these compds. as immunostimulants.

IT **76519-27-2 76519-28-3**
RL: BIOL (Biological study)
(neoplasm-inhibiting activity of cyclophosphamide and, structure in relation to)

RN 76519-27-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 76519-28-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:60766 CAPLUS
DOCUMENT NUMBER: 106:60766
TITLE: Pyrimidinones, a class of effective antitumor immunomodulators when used in combination with chemotherapeutic agents
AUTHOR(S): Li, L. H.; Wallace, T. L.; Wierenga, W.; DeKoning, T. F.
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, USA
SOURCE: Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th (1985), Volume Anticancer Sect. 1, 403-4. Editor(s): Ishigami, Joji. Univ. Tokyo Press: Tokyo, Japan.
CODEN: 55GNAX
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I

AB Of 10 pyrimidinones tested, only mono-halogen substitution at the ortho- or meta-position of Ph moiety of the 2-amino-5-halo-6-phenyl-4(3H)-pyrimidinones I (R1 = Br or I; R2 = Ph, C6H4Cl-3, C6H4F-3, C6H3Cl2-3,4, C6H3F2-2,3, C6H4NO2-3, C6H4OMe-3, 3-pyridyl) showed statistically significant synergism with cyclophosphamide (CY) [50-18-0]. I (R1 = Br; R2 = Ph), I (R1 = Br, R2 = C6H4F-3), and I (R1 = I, R2 = C6H4F-3) alone showed small but significant activity against B16 melanoma; however, they were ineffective against P388 leukemia, L1210 or M5076 tumors. Combination therapy proved to be additive or synergistic with CY against all tumors. The administration of I prior to CY was no better than the treatment with CY alone. A single injection of I 24 h following the CY administration was sufficient to produce a significant synergistic effect.

IT **76519-27-2 76519-28-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor activity of, alone and in combination with cyclophosphamide)

RN 76519-27-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 76519-28-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:596051 CAPLUS
DOCUMENT NUMBER: 103:196051
TITLE: Pyrimidinones. 1. 2-Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents
AUTHOR(S): Skulnick, Harvey I.; Weed, Sheldon D.; Eidson, Emerson E.; Renis, Harold E.; Stringfellow, Dale A.; Wierenga,

Wendell
CORPORATE SOURCE: Cancer Virus Res., Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Medicinal Chemistry (1985), 28(12), 1864-9
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:196051
GI



I

AB Title compds. I [R = Ph, halo-, alkoxy-, hydroxy-, nitro-, (trifluoromethyl)-, alkyl-, amino-, cyano-, carboxy-, or benzyloxyphenyl, naphthyl, furyl, pyridyl, pyrazinyl, quinolyl; R1 = Cl, Br, iodo] (about 110 compds.), which were prepd., exhibited virucidal activity. I (R = Ph, R1 = H) was halogenated by N-chlorosuccinimide in HOAc to give I (R = Ph, R1 = Cl).

IT **54950-11-7 54950-12-8 54950-13-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(halogenation of)

RN 54950-11-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-13-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



IT **76519-26-1P 76519-27-2P 76519-28-3P**
98305-53-4P 98305-54-5P 98305-55-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and virucidal activity of)
RN 76519-26-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 76519-27-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 76519-28-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 98305-53-4 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 98305-54-5 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 98305-55-6 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1985:471335 CAPLUS
DOCUMENT NUMBER: 103:71335
TITLE: Triazolopyrimidine derivatives and their use as cardiac stimulants
INVENTOR(S): Barthelemy, Gerard; Hallot, Andre; Vallat, Jean Noel
PATENT ASSIGNEE(S): SANOFI, Fr.
SOURCE: Fr. Demande, 13 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2549834	A1	19850201	FR 1983-12443	19830725
FR 2549834	B1	19851018		
IL 72330	A1	19870227	IL 1984-72330	19840706
US 4581358	A	19860408	US 1984-628916	19840709
ZA 8405301	A	19850227	ZA 1984-5301	19840710
AU 8430791	A1	19850131	AU 1984-30791	19840718
AU 562596	B2	19870611		
DK 8403605	A	19850126	DK 1984-3605	19840723
ES 534550	A1	19850501	ES 1984-534550	19840723
CS 248718	B2	19870212	CS 1984-5626	19840723

NO 8403003	A	19850128	NO 1984-3003	19840724
EP 136198	A1	19850403	EP 1984-401551	19840724
EP 136198	B1	19880210		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1226284	A1	19870901	CA 1984-459573	19840724
AT 32462	E	19880215	AT 1984-401551	19840724
FI 8402966	A	19850126	FI 1984-2966	19840725
JP 60051190	A2	19850322	JP 1984-155127	19840725
HU 34753	O	19850429	HU 1984-2861	19840725
HU 190653	B	19861028		
DD 222593	A5	19850522	DD 1984-265646	19840725
SU 1347865	A3	19871023	SU 1984-3767330	19840725
PRIORITY APPLN. INFO.:			FR 1983-12443	19830725
			EP 1984-401551	19840724

OTHER SOURCE(S): CASREACT 103:71335

GI



I



II



III

AB Triazolopyrimidinones I and II (R = alkyl; R1 = pyridyl, alkyl-, alkoxy-, hydroxy-, or cyanopyridyl; R2 = H, alkyl, unsatd. aliph. group), which were prepd., showed cardiovascular activity. Hydrazinopyrimidinone III was heated with MeC(OEt)3 in BuOH to give I (R = Me, R1 = 3-pyridyl, R2 = H).

IT **97545-24-9 97545-26-1 97545-28-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with ortho esters)

RN 97545-24-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(3-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



RN 97545-26-1 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 6-(2-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX

NAME)



RN 97545-28-3 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-(4-pyridinyl)-, 2-hydrazone (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1984:610998 CAPLUS
DOCUMENT NUMBER: 101:210998
TITLE: Dihydropyridinedicarboxylates
PATENT ASSIGNEE(S): Pfizer Corp., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59118782	A2	19840709	JP 1983-241806	19831221
JP 02025913	B4	19900606		
US 4572908	A	19860225	US 1983-562482	19831216
PL 140069	B1	19870331	PL 1983-245158	19831216
PL 140573	B1	19870530	PL 1983-250215	19831216
NO 8304689	A	19840622	NO 1983-4689	19831219
NO 159272	B	19880905		
NO 159272	C	19881214		
EP 116769	A1	19840829	EP 1983-307719	19831219
EP 116769	B1	19870325		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ES 528157	A1	19850801	ES 1983-528157	19831219
ZA 8309381	A	19850828	ZA 1983-9381	19831219
EP 168841	A2	19860122	EP 1985-109347	19831219
EP 168841	A3	19860219		
EP 168841	B1	19880928		
R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 26114	E	19870415	AT 1983-307719	19831219
IL 70477	A1	19870831	IL 1983-70477	19831219
FI 8304692	A	19840622	FI 1983-4692	19831220
FI 79104	B	19890731		
FI 79104	C	19891110		

AU 8322559	A1	19840628	AU 1983-22559	19831220
AU 546057	B2	19850815		
DK 8305865	A	19840727	DK 1983-5865	19831220
DD 213920	A5	19840926	DD 1983-258248	19831220
HU 32816	O	19840928	HU 1983-4351	19831220
HU 193275	B	19870928		
CA 1215050	A1	19861209	CA 1983-443770	19831220
SU 1296006	A3	19870307	SU 1983-3682597	19831220
CS 249516	B2	19870312	CS 1983-9668	19831220
SU 1391499	A3	19880423	SU 1984-3739756	19840508
ES 534723	A1	19850616	ES 1984-534723	19840730
CS 249525	B2	19870312	CS 1984-7453	19841001
US 4661485	A	19870428	US 1986-830292	19860214
US 4670449	A	19870602	US 1986-830384	19860214

PRIORITY APPLN. INFO.:

GB 1982-36347	19821221
US 1983-562482	19831216
EP 1983-307719	19831219
CS 1983-9668	19831220

OTHER SOURCE(S): CASREACT 101:210998

GI



AB Title compds. I [R = (un)substituted aryl, heteroaryl; R1, R2 = alkyl, MeOCH2CH2; R3 = (un)substituted heterocyclyl; Z = alkylene), useful as antihypertensives (data given on Ca++ transport inhibition), were prepd. Thus, treating amine II (R4 = H) with (MeS)2C:NCN gave II (R4 = MeSC:NCN) which was treated with N2H4 to give I (R = 2-ClC6H4, R1 = Me, R2 = Et, R3 = 2-amino-1H-1,2,4-triazol-5-yl, Z = CH2CH2).

IT **93118-63-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antihypertensive activity of)

RN 93118-63-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-2-[[2-[[1,4-dihydro-4-oxo-6-(2-pyridinyl)-2-pyrimidinyl]amino]ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1982:538234 CAPLUS
DOCUMENT NUMBER: 97:138234
TITLE: Interferon inducers as antiviral and antineoplastic agents
AUTHOR(S): Stringfellow, Dale A.
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: Curr. Chemother. Immunother., Proc. Int. Congr. Chemother., 12th (1982), Meeting Date 1981, Volume 2, 1118-19. Editor(s): Periti, Piero; Gialdroni Grassi, Giuliana. Am. Soc. Microbiol.: Washington, D. C. CODEN: 48HGAR
DOCUMENT TYPE: Conference
LANGUAGE: English
GI

Same as US 4,619,933



I

AB The correlation between interferon-inducing, antiviral (Semleki Forest and herpes simplex virus), and antitumor (B16 malignant melanoma) activities of 8 5-halo-6-arylpyrimidinones I (R = Br, I, or Cl; R1 = Ph, C6H4F-3, C6H4F-2, or pyridin-3-yl) was studied in mice. A good correlation existed between the interferon-inducing ability of the compds. with their inhibition of Semleki Forest virus but not herpes simplex virus. A direct correlation was obsd. between antiherpes activity and antitumor activity; no such direct correlation was found between interferon-inducing activity and antitumor activity. Thus, antiherpes activity of drugs may be a good predictor of antitumor activity against B19 melanoma in mice.

IT **76519-27-2**
RL: BIOL (Biological study)
(interferon-inducing and neoplasm-inhibiting and virucidal activity of)
RN 76519-27-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1981:84159 CAPLUS
DOCUMENT NUMBER: 94:84159
TITLE: 6-Arylpyrimidine derivatives
INVENTOR(S): Wierenga, Wendell; Skulnick, Harvey Irving; Stringfellow, Dale Alan; Fast, Patricia Evelyn
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: Ger. Offen., 82 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3008693	A1	19801002	DE 1980-3008693	19800306
DE 3008693	C2	19910314		
CH 646958	A	19841228	CH 1980-2043	19800314
NL 8001568	A	19800923	NL 1980-1568	19800317
GB 2048250	A	19801210	GB 1980-8979	19800317
GB 2048250	B2	19830427		
FR 2451918	A1	19801017	FR 1980-6015	19800318
FR 2451918	B1	19840106		
BE 882315	A1	19800919	BE 1980-199861	19800319
JP 55127378	A2	19801002	JP 1980-35729	19800319
JP 05002670	B4	19930113		
US 4507302	A	19850326	US 1981-303694	19810921
US 4543248	A	19850924	US 1982-366758	19820408
US 4619933	A	19861028	US 1983-526221	19830825
US 4665077	A	19870512	US 1984-630153	19840712
US 5002951	A	19910326	US 1987-46597	19870504
JP 05017451	A2	19930126	JP 1991-201754	19910812
JP 06027070	B4	19940413		
US 5434157	A	19950718	US 1993-7391	19930121
US 5554617	A	19960910	US 1995-419963	19950407

PRIORITY APPLN. INFO.:

US 1979-22205	19790319
US 1979-79850	19790928
US 1979-22025	19790319
US 1980-117314	19800131
US 1980-136436	19800420
US 1980-174947	19800804
US 1981-225159	19810115
US 1981-255159	19810115
US 1981-281820	19810709
US 1981-319358	19811109
US 1981-330360	19811214
US 1982-366758	19820408
US 1983-64791	19830207
US 1983-553738	19831121
US 1984-630153	19840712

US 1985-731326	19850503
US 1986-820871	19860115
US 1986-930027	19861110
US 1987-102311	19870925
US 1988-220877	19880718
US 1989-341238	19890418
US 1989-440452	19891121
US 1990-544814	19900627
US 1991-640532	19910114
US 1991-742580	19910807
US 1992-842726	19920226
US 1992-963236	19921019
US 1993-77813	19930616
US 1994-180006	19940111
US 1994-306212	19940914

GI



I

AB Arylpyrimidinols I (R = optionally substituted Ph, 1-naphthyl, 2-furyl, 3-pyridyl, 2-pyridyl, 2-pyrazinyl; R1 = halogen, alkyl, haloalkyl) were prepd. Thus I (R = Ph, R1 = Br) was obtained by brominating I (R = Ph, R1 = H). I (R = Ph, R1 = Br) stimulated interferon prodn. in cats at 50 mg/kg orally and protected calves against rhinotracheitis at 1 g/day for 6 days intranasally.

IT **76519-25-0P 76519-26-1P 76519-27-2P 76519-28-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 76519-25-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(2-pyridinyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 76519-26-1 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 76519-27-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-bromo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 76519-28-3 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-5-iodo-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1976:44112 CAPLUS
DOCUMENT NUMBER: 84:44112
TITLE: 4-Hydroxy-pyridylpyrimidine derivatives
INVENTOR(S): Tani, Hidero; Nakamura, Koji; Mori, Yasuhiro; Yokoo, Nobuo; Kyotani, Yoshinori; Wada, Yasushi
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49035631	B4	19740925	JP 1970-127611	19701228

PRIORITY APPLN. INFO.: JP 1970-127611 19701228
GI For diagram(s), see printed CA Issue.
AB Seven pyrimidinols (I, R = 2-, 3-, 4-pyridyl, R1 = H, Me, or R12N = morpholino), useful as antiinflammatory agents (no data), were prepd. from the corresponding pyridylcarbonylacetic acid ester and guanidine derivs. [R12NC(:NH)NH2]. E.g., 54.9 g nicotinoylacetic acid Me ester in 53 g

EtOAc was refluxed with EtO Na (obtained from 11.5 g Na and 200 ml EtOH) for 10 hr and the reaction mixt. was adjusted with H2SO4 to pH 7 to give 24.95 g nicotinoylacetic acid Et ester, which (18.1 g) was refluxed 5 hr with 12.6 g H2NC(:NH)NH2 carbonate in 60 ml EtOH to give I (R = 3-pyridyl, R1 = H).

IT **54950-11-7P 54950-12-8P 54950-13-9P**
54950-14-0P 54950-15-1P 54950-16-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 54950-11-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-13-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-15-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1975:410129 CAPLUS
DOCUMENT NUMBER: 83:10129
TITLE: 2-(Substituted)-4-hydroxy-6-pyridylpyrimidine derivatives
INVENTOR(S): Tani, Hidero; Nakamura, Koji; Mori, Yasuhiro; Yokoo, Nobuo; Kyotani, Yoshinori; Wada, Yasushi
PATENT ASSIGNEE(S): Mori, Hiroshi
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49035634	B4	19740925	JP 1970-128203	19701230

PRIORITY APPLN. INFO.: JP 1970-128203 19701230
GI For diagram(s), see printed CA Issue.
AB Seven 2-amino-6-pyridyl-4-pyrimidinols (I, R = H2, Me, or R2N = morpholino; R1 = 2-, 3-, or 4-pyridyl), useful as antiinflammatory agents, were prepd. from the 2-(methylthio) derivs. and the appropriate amines. E.g., 3.0 g 2-(methylthio)-6-(4-pyridyl)-4-pyrimidinol, obtained from reaction of H2NC(:S)NH2 with Et isonicotinoylacetate and subsequent methylation, was treated with 260 mg Me2NH in BuOH at 150.degree. for 2 hr to give 76.5% I (R = Me, R1 = 4-pyridyl).
IT **54950-11-7P 54950-12-8P 54950-13-9P**
54950-14-0P 54950-15-1P 54950-16-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 54950-11-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-12-8 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-13-9 CAPLUS
CN 4(1H)-Pyrimidinone, 2-amino-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-15-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54950-16-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1975:410127 CAPLUS
DOCUMENT NUMBER: 83:10127
TITLE: 5-Nitro-6-pyridylprimidine derivatives
INVENTOR(S): Tani, Hidero; Nakamura, Koji; Yokoo, Nobuo; Kyotani, Yoshinori; Akaishi, Keisuke
PATENT ASSIGNEE(S): Mori, Hiroshi
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49035633	B4	19740925	JP 1970-128199	19701230

PRIORITY APPLN. INFO.: JP 1970-128199 19701230
GI For diagram(s), see printed CA Issue.
AB Three 5-nitro-2-amino-4-(4-pyridyl)pyrimidines (R = H, Me; R1 = OH, NH2), useful as antiinflammatory agents, were prepd. by nitration of the corresponding II. Thus, 15 g II (R = Me, R1 = NH2) was treated with a mixt. of 10 ml fuming HNO3 and 50 ml H2SO4 for 1 hr and the mixt. was treated with 28% NH3-H2O to give 8.08 g I (R = Me, R1 = NH2).
IT **54950-14-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)
RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **55361-89-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 55361-89-2 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-nitro-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1975:171028 CAPLUS
DOCUMENT NUMBER: 82:171028
TITLE: 2,4,5-Trisubstituted-6-pyridylpyrimidine derivatives
INVENTOR(S): Tani, Hideo; Nakamura, Koji; Yokoo, Nobuo; Kyoya, Yoshinori; Akashi, Keisuke
PATENT ASSIGNEE(S): Mori, Hiroshi
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49036719	B4	19741002	JP 1970-128201	19701230

PRIORITY APPLN. INFO.: JP 1970-128201 19701230
GI For diagram(s), see printed CA Issue.
AB Pyridylpyrimidinols [I, R = 1-piperidinylmethyl (II), morpholinomethyl], useful as antiinflammatory agents (no data), were prepd. by reacting I (R = H) with RH and formalin. E.g., 650 mg I (R = H) was refluxed with 0.036 ml HOAc, 306 mg piperidine, 0.375 ml formalin and 6 ml EtOH for 45 min, the mixt. allowed to stand for 2.5 hr, 0.1 ml formalin added, and the mixt. again refluxed for 1.5 hr to give 44 mg II. II.cntdot.HCl was also prepd.
IT **55362-49-7P 55362-50-0P 55362-51-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 55362-49-7 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-(1-piperidinylmethyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 55362-50-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-(1-piperidinylmethyl)-6-(4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 55362-51-1 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-5-(4-morpholinylmethyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



IT **54950-14-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction with amines and formaldehyde)
RN 54950-14-0 CAPLUS
CN 4(1H)-Pyrimidinone, 2-(dimethylamino)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1975:140173 CAPLUS
DOCUMENT NUMBER: 82:140173
TITLE: 2,4,6-Trisubstituted pyrimidines
INVENTOR(S): Tani, Hideo; Nakamura, Koji; Mori, Shizuhiro; Yokoo, Nobuo; Kyotani, Yoshitoku; Wada, Yasushi
PATENT ASSIGNEE(S): Kowa Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 12 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49021148	B4	19740530	JP 1970-127609	19701228

PRIORITY APPLN. INFO.: JP 1970-127609 19701228

GI For diagram(s), see printed CA Issue.

AB Sixty-three antiinflammatory (no data) pyrimidines (R = 4-pyridyl, Ph, etc., R1 = NH2, NMe2, NEt2, morpholino, NHPr, piperidino, OMe, etc., R2 = NMe2, OCH2CH2NMe2, NEt2, morpholino, NHCH2CH:CH2, NHCH2CH2OH, etc.) were prepd. by reacting I (R1 = SO2Me or Cl) with the appropriate amine or alc. E.g., I (R = NH2, R1 = SO2Me, R2 = 4-pyridyl) (0.016 mole) was refluxed 1 hr with 30 ml MeOH contg. 0.03 mole Na to give 80% I (R = NH2, R1 = OMe, R2 = 4-pyridyl).

IT **54993-99-6P 54994-00-2P 54994-01-3P**
54994-02-4P 54994-03-5P 54994-04-6P
54994-06-8P 54994-07-9P 54994-13-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 54993-99-6 CAPLUS
CN 2-Pyrimidinamine, 4-methoxy-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-00-2 CAPLUS
CN 2-Pyrimidinamine, 4-ethoxy-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-01-3 CAPLUS
CN 2-Pyrimidinamine, 4-butoxy-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-02-4 CAPLUS
CN 2-Pyrimidinamine, 4-(phenylmethoxy)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-03-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(dimethylamino)ethoxy]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-04-6 CAPLUS
CN 2-Pyrimidinamine, 4-[3-(diethylamino)propoxy]-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-06-8 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(diethylamino)ethoxy]-N,N-dimethyl-6-(4-pyridinyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 54994-07-9 CAPLUS
CN 2-Pyrimidinamine, 4-[3-(dimethylamino)propoxy]-N,N-dimethyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 54994-13-7 CAPLUS
CN 2-Pyrimidinamine, 4-methoxy-N,N-dimethyl-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1966:490645 CAPLUS
DOCUMENT NUMBER: 65:90645
ORIGINAL REFERENCE NO.: 65:16966b-h,16967a-e
TITLE: Pyrimidines series. XVIII. Synthesis and reactions of 4-chloro-5-nitropyrimidines
AUTHOR(S): Buehler, Eberhard; Pfleiderer, Wolfgang
CORPORATE SOURCE: Tech. Hochsch., Stuttgart, Germany
SOURCE: Chem. Ber. (1966), 99(9), 2997-3007
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB cf. preceding abstr. The synthesis of new 4-chloro-5-nitropyrimidines is described; their reactivity towards various nucleophilic reagents was investigated. 4-Chloro-1,3-dimethyluracil (I) (42.5 g.) in 125 cc. concd. H2SO4 treated <15.degree. with stirring dropwise with 42 cc. fuming HNO3 (d. 1.5) and stirred into 500-600 g. ice yielded 49.5 g. (crude) pale yellow 5-NO2 deriv. of I, m. 80-3.degree. (sublimed in vacuo at 70-5.degree.). 2-Amino-4-chloro-6-methoxypyrimidine (II) (3 g.) in 6 cc. concd. H2SO4 treated dropwise at room temp. with 3 cc. fuming HNO3, heated 15 min. at 65-70.degree., cooled to 0.degree., and stirred into 50 g. crushed ice gave 1 g. pale yellow 5-NO2 deriv. (III) of II, m.

177-9.degree. (sublimed at 90.degree./0.01 mm.). 4-Chloro-6-methoxy-2-nitraminopyrimidine (IV) (0.5 g.) in 1 cc. H2SO4 heated 15 min. at 70.degree. and poured onto ice gave pale yellow III, m. 177-9.degree. (H2O). 4-Chloro-2-dimethylamino-6-methoxypyrimidine (V) (10 g.) in 20 cc. concd. H2SO4 treated dropwise at 0-5.degree. with 10 cc. fuming HNO3 gave 6.6 g. light yellow 5-NO2 deriv. (VI) of V, m. 114-16.degree. (EtOH). II (5 g.) in 10 cc. concd. H2SO4 treated at 0-5.degree. with 5 cc. fuming HNO3 and kept 1 hr. at room temp. yielded 2.4 g. IV, m. 120-2.degree. (ligroine). IV (1 g.) in 60 cc. EtOH hydrogenated at room temp. over Raney Ni gave 0.55 g. II, m. 165.degree.. 2,6-Diamino-4-chloropyrimidine (VII) (4 g.) in 8 cc. concd. H2SO4 treated slowly with stirring and cooling with 4 cc. fuming HNO3 yielded 2.5 g. pale yellow 2-O2NNH analog of VII, m. 227.degree.. Guanidine carbonate (VIII) (0.88 g.), 0.22 g. Na, and 30 cc. EtOH refluxed 10 min., treated with 1 g. 2-amino-4-chloro-1-methyl-5-nitro-6-oxodihydropyrimidine (IX), and refuxed 2 hrs. gave 0.25 g. yellow 4-H2NC(:NH)NH analog of IX, m. 229-31.degree. (decompn.) (H2O). IX (2 g.) and 0.75 g. urea in 40 cc. EtOH refluxed 0.5 hr. and kept overnight yielded 1.75 g. pale yellow 4-H2NC(:NH)O analog of IX, m. 187-9.degree. (decompn.) (EtOH). VIII (5.25 g.), 1.35 g. Na, and 120 cc. EtOH refluxed 10 min., treated with 6 g. 4-chloro-2-dimethylamino-5-nitropyrimidine, refluxed 1 hr., and kept overnight gave 3 g. light yellow needles, m. 191-3.degree. (decompn.). N-(2-Amino-1-methyl-4-nitro-6-oxo-4-dihydropyrimidinyl)pyridinium chloride (1.4 g.) in 50 cc. abs. EtOH refluxed 1.5 hrs. with 1.3 cc. PhNH2 yielded 0.8 g. 2-amino-4-anilino-1-methyl-5-nitro-6-oxodihydropyrimidine (X), m. 292-4.degree. (decompn.) (EtOH). IX (1 g.) and 1.3 cc. PhNH2 in 45 cc. EtOH refluxed 0.5 hr. yielded 0.95 g. X. 2-Amino-4-chloro-5-nitro-6-oxodihydropyrimidine (XI) (1 g.) and 4 g. 2-aminopyridine (XII) in 100 cc. abs. EtOH refluxed 75 min. gave 0.45 g. 4-(2-pyridylamino) analog (XIII) of XI, m. 305-7.degree. (decompn.). XIII (1 g.) in 50 cc. MeOH hydrogenated at room temp. over Raney Ni, treated with 2 cc. AcCO2Et, filtered, and refluxed 1.5 hrs. yielded 0.2 g. pale yellow XIV, m. from 305.degree. (decompn.). 4-Chloro-2-dimethylamino-5-nitropyrimidine (XV) (2 g.) and 4 g. XII fused about 10 min. at 70.degree. gave 1.3 g. 4-(2-pyridylamino) analog (XVI) of XV, m. 210-12.degree.. XV (2 g.) and 4 g. 3-aminopyridine gave similarly 1.8 g. pale yellow 4-(3-pyridylamino) analog of XV, m. 219-21.degree. (EtOH). 2-Amino-4-chloro-6-methoxy-5-nitropyrimidine (0.5 g.) and 2 g. XII fused at 100.degree. gave 0.25 g. pale yellow 4-(2-pyridylamino) analog of II, m. 213-15.degree. (EtOH). XVI (0.5 g.) in 30 cc. MeOH hydrogenated over Raney Ni, treated with 0.5 cc. AcCO2Et, filtered, and refluxed 0.5 hr. yielded 0.15 g. pale yellow XVII, m. 203-4.degree. (decompn.) (ligroine). 2,4,5-Triamino-1-methyl-6-oxodihydropyrimidine dihydrochloride (4.6 g.), 0.92 g. Na, and 100 cc. EtOH refluxed 15 min., cooled to room temp., treated with 2 g. IX, and refluxed 40 min. gave 2.2 g. light yellow XVIII, m. >350.degree. (decompn.) (2N HCl). XV (1 g.) and 1.5 g. 4,6-diamino-2-dimethylaminopyrimidine (XIX) in 50 cc. BuOH refluxed 4 hrs., cooled overnight, and filtered, and the residue boiled with 750 cc. xylene left XIX. HCl; the filtrate deposited overnight 0.33 g. orange XX, m. 241-3.degree. (EtOH). XI (0.5 g.) in 6 cc. dry HCONMe2 heated 5 min. at 80.degree. with 1 cc. abs. C5H5N gave 0.5 g. XXI (R = H) (XXII), m. 210.degree. (decompn.). XXII (0.55 g.) in 8 cc. H2O adjusted with solid NaHCO3 to pH 8-9 and kept several hrs. at room temp. yielded 0.15 g. yellow N-(2-amino-5-nitro-6-oxo-4-pyrimidinyl)pyridinium betaine, m. >200.degree. (decompn.) (H2O). IX (0.5 g.) in 7 cc. dry C5H5N heated briefly to boiling yielded 0.7 g. light yellow XXI (R = Me) (XXIII), m. 200-2.degree. (decompn.). XV (0.5 g.) in 5 cc. dry C5H5N gave similarly 0.6 g. XXIV, m. 163-4.degree.. 4-Chloro-5-nitrouracil (XXV) (1 g.) in 5 cc. dry HCONMe2 and 2 cc. dry C5H5N heated to 80.degree. gave 0.8 g. light yellow XXVI (R = R' = R'' = H) (XXVII), m. 251.degree. (decompn.) (H2O). XXV (1 g.), 1. cc. 3-picoline, and 5 cc. HCONMe2 gave similarly 0.75 g. light yellow XXVI (R = R'' = H, R' = Me) (XXVIII), m. >260.degree. (decompn.) (H2O). XXV (1 g.) and 1.5 cc. dry 4-picoline in 5 cc. HCONMe2 yielded 0.75 g. yellow XXVI (R = R' = H, R'' = Me) (XXIX), m. from

240.degree. (decompn.) (H2O). 1-Me deriv. (0.5 g.) of XXV, 1 cc. dry C5H5N, and 4 cc. dry HCONMe2 gave similarly 0.45 g. light yellow XXVI (R = Me, R' = R'' = H) (XXIXa), m. 260.degree. (decompn.) (H2O). XXII (1 g.) in 15 cc. H2O refluxed 10 min. gave 0.5 g. 2-amino-4-hydroxy-5-nitro-6-oxodihydropyrimidine (XXX), m. above 350.degree.. XXIII (0.85 g.) in 10 cc. H2O refluxed 5 min. yielded 0.4 g. 1-Me deriv. (XXXI) of XXX, m. 300-2.degree. (decompn.) (H2O). IX (3 g.) in 30 cc. N NaOH refluxed 1 hr. and acidified with 2N HCl gave 0.5 g. XXXI, m. 297.degree. (decompn.) (very dil. HCl). XI (0.4 g.) in 100 cc. MeOH and 5 cc. dry C5H5N refluxed 0.45 min. gave 0.3 g. 2-amino-4-methoxy-5-nitro-6-oxodihydropyrimidine (XXXII), m. from 274.degree. (decompn.) (H2O). IX (1.2 g.) in 25 cc. MeOH refluxed 50 min. with 5 cc. dry C5H5N gave 0.6 g. lemon-yellow 1-Me deriv. (XXXIII) of XXXII, m. 214-16.degree. (MeOH). XXIV (1.5 g.) in 20 cc. abs. EtOH refluxed briefly with 1.1 g. XII yielded 0.3 g. orange XXXIV, m. 154-6.degree. (decompn.) (CHCl3). XV (3 g.) and 0.48 g. Na in 20 cc. EtOH refluxed 45 min. gave 1.9 g. pale yellow 4-EtO analog (XXXV) of XXXIV, m. 104-6.degree. (sublimed at 80.degree. in vacuo). XXIV (2.2 g.) in 5 cc. abs. EtOH refluxed 1.5 hrs. gave 0.5 g. XXXV. The pK values in H2O at 20.degree. (given) were detd. for the following compds.: XXVII -0.80 .+-. 0.07, XXVIII -0.12 .+-. 0.05, XXIX 0.14 .+-. 0.01, XXIXa -0.39 .+-. 0.1, XXII, 3.16 .+-. 0.18, XXXI 5.55 .+-. 0.07, XXXII 7.41 .+-. 0.07, XXXIII 1.25 .+-. 0.04, XIV 8.15 .+-. 0.09, XVII 2.04 .+-. 0.02.

IT **7637-73-2**, Pyridinium, 1-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, hydroxide, inner salt **7637-74-3**, Pyridinium, 1-(2-amino-1,6-dihydro-1-methyl-5-nitro-6-oxo-4-pyrimidinyl)-, chloride **7695-14-9**, Pyridinium, 1-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, chloride
(prepn. of)

RN 7637-73-2 CAPLUS

CN Pyridinium, 1-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 7637-74-3 CAPLUS

CN Pyridinium, 1-(2-amino-1,6-dihydro-1-methyl-5-nitro-6-oxo-4-pyrimidinyl)-, chloride (9CI) (CA INDEX NAME)



RN 7695-14-9 CAPLUS

CN Pyridinium, 1-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, chloride (9CI) (CA INDEX NAME)



● Cl^-

```
=> d his

     (FILE 'HOME' ENTERED AT 16:18:33 ON 30 JAN 2003)

     FILE 'REGISTRY' ENTERED AT 16:18:43 ON 30 JAN 2003
L1               STRUCTURE UPLOADED
L2             5 S L1
L3           396 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 16:19:27 ON 30 JAN 2003
L4            31 S L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     141.45     289.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -20.18     -20.18

STN INTERNATIONAL LOGOFF AT 16:20:45 ON 30 JAN 2003
```